IARTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
INTEGRA LIFESCIENCES HOLDINGS CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Oct 23, 2026
$13.45+0.24 (+1.82%)
Close on Oct 19, 2026
- Market cap
- $1.05B
- P/E (TTM)
- –
- Dividend yield
- –
INTEGRA LIFESCIENCES HOLDINGS CORP revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Surgery | – | – | $1.20B | $1.19B | $1.17B | $1.17B | $1.14B | $1.10B | $1.10B | $1.07B | $1.06B | $1.05B | – | – |
| Tissue Technologies | – | – | $434.73M | $451.10M | $451.68M | $456.44M | $466.89M | $464.32M | $468.49M | $462.31M | $482.58M | $490.59M | – | – |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Specialty Surgery | – | – | $120.88M | $113.44M | $83.75M | $510.95M | $504.07M | $486.26M | $490.89M | $443.09M | $450.53M | $442.24M | – |
| Tissue Technologies | – | – | -$31.07M | -$19.01M | -$17.67M | $124.55M | $139.17M | $138.25M | $141.56M | $112.43M | $134.05M | $150.66M | – |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.21B | $1.21B | $1.20B | $1.22B | $1.21B | $1.22B | $1.19B | $1.14B | $1.12B | $1.09B | $1.10B | $1.11B | 73.6% | -0.2% |
| Asia Pacific | $190.32M | $189.36M | $189.25M | $179.58M | $173.96M | $172.17M | $176.61M | $178.69M | $190.41M | $192.17M | $193.10M | $189.58M | 11.6% | +9.4% |
| Europe | $167.28M | $167.30M | $162.67M | $162.66M | $154.13M | $152.23M | $158.50M | $161.83M | $168.99M | $165.75M | $165.22M | $162.04M | 10.2% | +8.5% |
| Rest of World | $77.36M | $75.94M | $78.58M | $80.33M | $78.91M | $81.25M | $82.74M | – | – | – | – | – | 4.7% | -2.0% |
| Rest of World | – | – | – | – | – | – | – | $84.64M | $87.70M | $85.72M | $82.53M | $79.23M | – | – |
From the segment and revenue-disaggregation notes of Integra Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.